Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. We are developing a novel proprietary technology that permits the isolation of pure and defined stomal cells from human tissue and a range of other species. The multi-species elements allow our technology to move seamlessly from the research laboratories to the clinic. The technology is designed to ensure that resulting therapies comply with the forthcoming stringent EMA and UK BSI guidelines regarding the purity and definition of cellular therapies. We believe that our technology will set the standard for regenerative medicine into the future. Orbsen Therapeutics was originally formed in 2006 as a spin out company from REMEDI, Ireland's Regenerative Medicine Institute in NUI Galway. Founded and led by some of the leading scientists in the field of regenerative medicine we operate from within the Orbsen Building, on campus at NUI Galway, which houses REMEDI's state of the art research facilities. The company has already participated in EU FP7 funded research progammes and has a significant research pipeline coming to fruition over the coming years.